logo_albo

About the Company

Albireo Pharma (NasdaqCM: ALBO) is a clinical-stage biotechnology company focused on the development of bile acid modulators for the treatment of liver and gastrointestinal diseases. The Company’s lead drug candidate A4250 is being developed for the treatment of several cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC). A4250 is being studied in a Phase II trial for pediatric cholestatic pruritus, and data from the fifth of six cohorts are expected this year. Albireo recently went public via a share exchange agreement with Biodel, which functioned as a reverse merger and capitalized the Company with $30 million. Albireo now has sufficient capital to fund a planned pivotal trial with A4250 in PFIC.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research